Author:
Smit Cornelis,Wasmann Roeland E.,Goulooze Sebastiaan C.,Hazebroek Eric J.,Van Dongen Eric P. A.,Burgers Desiree M. T.,Mouton Johan W.,Brüggemann Roger J. M.,Knibbe Catherijne A. J.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference42 articles.
1. EUCAST. Gentamicin: rationale for the EUCAST clinical breakpoint (version 1.2). 2009.
http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Gentamicin_rationale_1.2_0906.pdf
. Accessed 2 Apr 2019.
2. USCAST: United States Committee on Antimicrobial Susceptibility Testing. Aminoglycoside in vitro susceptibility test interpretive criteria evaluations, version 1.1. USCAST; 2016.
http://www.uscast.org/
. Accessed May 2018.
3. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetics parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988;158:831–47.
4. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984;77:657–62.
5. Mouton JW, Jacobs N, Tiddens H, Horrevorts AM. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn Microbiol Infect Dis. 2005;52:123–7.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献